Published Date: 27 Apr 2023
The field is reaching a point where sleep health will become a top priority for public health as a result of the great strides made in the field over the past year, as well as the effects of the COVID-19 pandemic and lingering care challenges.
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Allison B. Reiss, MD, associate professor of medicine at NYU Grossman Long Island School of Medicine discussed the often-overlooked early signs of early-onset Alzheimer disease.
Gefurulimab (Klygefa), a once-weekly, self-administered complement C5 inhibitor from Alexion and AstraZeneca, is now approved in the US for adults with AChR-antibody-positive generalized myasthenia gravis.
A new FDA filing seeks to expand cenobamate's epilepsy indication to primary generalized tonic-clonic seizures, based on positive phase 3 trial data.
The professor of neurology at UT Southwestern Medical Center discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.
A new global phase 2 trial, TARBELA-AD, will test RG6434, Roche's investigational oral NLRP3 inflammasome inhibitor, in adults with early symptomatic Alzheimer disease.
A pivotal phase 2/3 trial of Zhimeng Biopharma's CB03-154, an oral KCNQ2/3 potassium channel opener, has completed enrollment in amyotrophic lateral sclerosis.
1.
The Growing Role of AI in Cancer Treatment
2.
Formaldehyde Causes More Cancer Than Any Other Toxic Air Pollutant
3.
Mapping lifelong chronic health risks for childhood cancer survivors
4.
AI-based liquid biopsy shows promise for detecting brain cancer
5.
Advanced imaging, targeted therapy help men with prostate cancer safely defer surgery and radiation therapy
1.
Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions
2.
Preventing Transfusion-Associated Iron Accumulation
3.
Tumor Microenvironment Readiness as a Predictor of Cancer Progression
4.
Risk Assessment of Neurologic Toxicity From Cancer Treatment
5.
Molecular Classification of Treatment-Refractory Anemia
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
5.
Predicting Delayed Hemolytic Transfusion Reactions Through Donor-Recipient Antigen Exposure Modeling
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation